Work

A randomized phase III trial investigating platinum and taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) patients with alterations in DNA damage response (DDR) genes (OPTION-DDR) CCTG-PR-25 NCT06439225.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.tps5143

Authors: Michael Ong, Michael Paul Kolinsky, Kim N. Chi, Sebastien J. Hotte, Michael Donald Brundage, Daniel Joseph Khalaf, David Boren, M. Neil Reaume, Alexander William Wyatt, Wendy R. Parulekar, Keyue Ding, Mariam Jafri

Institutions: Ottawa Hospital, Cross Cancer Institute, University of British Columbia, Juravinski Cancer Centre, Kingston General Hospital, Sunnybrook Health Science Centre, Odette Cancer Centre, Canadian Cancer Trials Group, University of Ottawa, Queen's University

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Canadian Institutes of Health Research

OpenAlex ID: W7162680112

Cites:

Cited by:

Related to: